Ads
related to: belimumab activating factor serum side effects- Dosing & Admin Info
Learn About Dosing & Administration
And Find Helpful Resources & Info.
- Risks And Side Effects
Read The Potential Risks & Common
Side Effects That May Occur.
- BENLYSTA Cares
Talk To Trained Nurses Live To Ask
Questions About The Medication Now.
- Find Patient Information
Learn More About BENLYSTA
On The Official Patient Website.
- BENLYSTA Cares Line
Call Trained Nurses Who Can Answer
Questions About Taking Benlysta.
- Free Tools & Support
Find Injection Training And Support
On The Official Patient Website.
- Dosing & Admin Info
Search results
Results From The WOW.Com Content Network
Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), [6] also known as B-lymphocyte stimulator (BLyS). [7] It is approved in the United States [ 8 ] and Canada, [ 9 ] and the European Union [ 5 ] to treat systemic lupus erythematosus and lupus nephritis.
nerve growth factor (NGF) [36] Y: pain associated with osteoarthritis in dogs [36] Begelomab [6] mab: mouse: DPP4: Belantamab mafodotin [5] Blenrep: mab: humanized: B-cell maturation antigen (BCMA) Y (Withdrawn) relapsed or refractory multiple myeloma Belimumab [37] Benlysta: mab: human: B-cell activating factor (BAFF) Y: systemic lupus ...
B-cell activating factor (BAFF) also known as tumor necrosis factor ligand superfamily member 13B and CD257 among other names, is a protein that in humans is encoded by the TNFSF13B gene. [ 5 ] [ 6 ] BAFF is also known as B Lymphocyte Stimulator (BLyS) and TNF- and APOL-related leukocyte expressed ligand (TALL-1) and the Dendritic cell-derived ...
For premium support please call: 800-290-4726 more ways to reach us
Antibody-directed enzyme prodrug therapy (ADEPT) involves the application of cancer-associated monoclonal antibodies that are linked to a drug-activating enzyme. Systemic administration of a non-toxic agent results in the antibody's conversion to a toxic drug, resulting in a cytotoxic effect that can be targeted at malignant cells.
A TNF-α (tumor necrosis factor-alpha) binding protein is a monoclonal antibody or a circulating receptor such as infliximab (Remicade), etanercept (Enbrel), or adalimumab (Humira) that binds to TNF-α, preventing it from inducing the synthesis of IL-1 and IL-6 and the adhesion of lymphocyte-activating molecules.
The most common side effects include headache, high blood pressure, urinary tract infection (infection of the structures that carry urine), upper respiratory tract infection (nose and throat infection), nasopharyngitis (inflammation of the nose and throat), nausea, abdominal pain, infusion-related reactions and cyanosis (bluish discoloration of ...
For premium support please call: 800-290-4726 more ways to reach us
Ads
related to: belimumab activating factor serum side effects